Wednesday, 14 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 28, 2026

Coca-Cola Reports First Quarter 2026 Results and Updates Full Year Guidance

View original at finance.yahoo.com
“Cash flow: Cash flow from operations and free cash flow (non-GAAP) were $2.0 billion and $1.8 billion, respectively.”
Verbatim excerpt from the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Comparable operating margin expansion was driven by organic revenue growth and lower operating expenses, partially offset by higher input costs and increased marketing investments

    60% confidence

  • Global unit case volume grew 3% in Q1 2026

    60% confidence

  • Operating income grew 19%; comparable currency neutral operating income grew 12% in Q1 2026

    60% confidence

  • The company gained value share in total non-alcoholic ready-to-drink beverages in Q1 2026

    60% confidence

  • Operating margin was 35.0% versus 32.9% in the prior year; comparable operating margin was 34.5% versus 33.8% in the prior year

    60% confidence

  • Cash flow from operations was $2.0 billion and free cash flow was $1.8 billion in Q1 2026

    60% confidence

  • By leveraging key consumption occasions and local insights, the company increased weekly drinkers and gained value share globally during Q1 2026

    60% confidence

  • Coca-Cola set a Guinness World Record in Egypt for the most community meals served in one hour during Ramadan

    60% confidence

  • In the Philippines, single-serve Coca-Cola Zero Sugar packs grew double digits and delivered away-from-home volume growth

    60% confidence

  • EPS grew 18% to $0.91 in Q1 2026, with a 6-point currency tailwind; comparable EPS grew 18% to $0.86 with a 3-point currency tailwind

    60% confidence

  • In North America, mini-can volume grew high single digits following the launch of single-serve mini-cans in convenience retail stores

    60% confidence

  • Net revenues grew 12% to $12.5 billion in Q1 2026, and organic revenues grew 10%, driven by an 8% increase in concentrate sales and 2% growth in price/mix

    60% confidence

  • Sprite delivered double-digit volume growth in Brazil, supported by brand-led activations tied to Carnival and summer festivals

    60% confidence

  • Coca-Cola had a strong start to 2026 with performance reflecting unwavering focus on staying close to the consumer, executing locally and managing complexity

    60% confidence

  • Concentrate sales were 5 points ahead of unit case volume in Q1 2026, primarily due to six additional days in the quarter

    60% confidence

Data points we hold from this source

The Coca-Cola Company · concentrate sales growth8 percent
The Coca-Cola Company · operating income growth19 percent
The Coca-Cola Company · free cash flow1.8 USD
The Coca-Cola Company · comparable eps0.86 USD
The Coca-Cola Company · comparable currency neutral operating income growth12 percent
The Coca-Cola Company · margin35.0 percent
The Coca-Cola Company · unit case volume growth3 percent
The Coca-Cola Company · comparable operating margin34.5 percent
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com
Coca-Cola Reports First Quarter 2026 Results and Updates Full Year Guidance — Source | Via News | ViaNews EU